Fig. 4: Anticancer activity and improved immune microenvironment of Met@Man-MPs in H22 tumor-bearing mice.

a Tumor growth curves of H22 tumor-bearing mice after intravenous injection of PBS, MPs, Man-MPs, free Met, Met@MPs or Met@Man-MPs at the Met dosage of 10 mg kg⁻¹, or high dosage of Met at 100 mg kg⁻¹ every two days for six times. The black arrows indicate the injection time. Data are presented as mean ± s.e.m. (n = 5 mice per group; two-way ANOVA followed by Bonferroni’s multiple comparisons post-test). b Tumor weight at the end of the treatment indicated in (a). Data are presented as mean ± s.d. (n = 5 mice per group; one-way ANOVA followed by Tukey’s HSD post-hoc test). c Kaplan–Meier survival plot of H22 tumor-bearing mice after treatment indicated in (a) (n = 7 mice per group). d–k The numbers of M1-like TAMs (d), M2-like TAMs (e), CD8⁺ T cells (f), CD8⁺CD69⁺ T cells (g), CD4⁺ T cells (h), CD4⁺CD69⁺ T cells (i), MDSCs (j), and Tregs (k) in tumor tissues of H22 tumor-bearing mice after intravenous injection of PBS, MPs, Man-MPs, free Met, Met@MPs or Met@Man-MPs at the Met dosage of 10 mg kg⁻¹, or high dosage of Met at 100 mg kg⁻¹ every two days for six times. Data are presented as mean  ± s.d. (n = 3 mice per group; one-way ANOVA followed by Tukey’s HSD post-hoc test). l–o The contents of IFN-γ (l), TNF-α (m), IL12p70 (n), and TGF-β (o) in tumor tissues of H22 tumor-bearing mice after intravenous injection of PBS, MPs, Man-MPs, free Met, Met@MPs or Met@Man-MPs at Met dosage of 10 mg kg⁻¹, or high dosage of Met at 100 mg kg⁻¹ every two days for six times. Data are presented as mean ±  s.d. (n = 3 mice per group; one-way ANOVA followed by Tukey’s HSD post-hoc test). Source data are provided as a Source Data file.